In both studies, animals were randomized by sex to receive vehicle (formulation buffer) or PG-102 and were administered subcutaneously once weekly
I think the more interesting question is how do we design benefits that improve health outcomes and remain sustainable
This effect became statistically significant from the tenth day of the study onward, as patients were titrated to increasingly higher doses of liraglutide
Dosing, Titration, and Tolerability Wegovy is administered once weekly using a small subcutaneous injection
You meet the CMS health requirements, such as being diagnosed with obesity
This reflects several practical and risk-management considerations: Feasibility: 10 mg represents a testable dose that fits typical tablet manufacturing and is easy to dose consistently Precaution: It is substantially lower than the upper range of animal studies when adjusted for expected human bioavailability Tolerability: Community reports suggest 10 mg daily is generally well-tolerated in most users without major adverse effects Observability: At lower doses, any effects (beneficial or adverse) are more likely to be attributable to Dihexa rather than confounding factors Cost-effectiveness: 10 mg balances efficacy expectations with pricing practicality However, "conservative" and "well-tolerated at low doses" does not mean "safe." The absence of clinical trial data means individual responses are unpredictable
